

NMSB2

RECEIVED
REGION I
2008 MAR 10 AM 10:23

March 7, 2008

Mr. James P. Dwyer, Chief
Commercial and R&D Branch
Division of Nuclear Materials Safety
U.S. Nuclear Regulatory Commission, Region I
475 Allendale Road
King of Prussia, Pennsylvania 19406-1415

03019868

Re: Request for Prior Written Consent to Indirect Transfer of Control of
Materials License No. 29-21169-01

Dear Mr. Dwyer:

Safeguard Scientifics, Inc., a Pennsylvania corporation ("Safeguard"), Saints Capital Dakota, L.P., a Delaware limited partnership ("Saints"), and Laureate Pharma, Inc., a Delaware corporation ("Laureate" or the "Licensee"), hereby request prior written consent to a planned indirect transfer of control of the above-captioned license under Section 184 of the Atomic Energy Act of 1954 as amended, 10 CFR 30.34(b), 10 CFR 40.46, and 10 CFR 70.36. Laureate is currently wholly-owned by Safeguard Delaware, Inc. ("SDI"), which is a wholly-owned subsidiary of Safeguard. In the proposed transaction, Saints will purchase all of SDI's ownership interest in Laureate, and Saints will become the sole stockholder of Laureate. Laureate will be unchanged by the transaction, except that Laureate will be wholly-owned by Saints rather than Safeguard, and there will be two (2) new directors of Laureate.

The proposed indirect transfer does not involve any change in licensed activities. Further information supporting this request for prior written consent to an indirect transfer of control is provided below in Attachment 1.

The closing of the proposed transaction is expected to occur within the next two months, but it is dependent upon the receipt of the prior written consent requested herein. No other approvals are required. As such, Safeguard, Saints and Laureate respectfully request that this request for prior written consent be reviewed, and such consent provided, expeditiously.

If you have any questions or comments, please contact Robert J. Broeze, the President and Chief Executive Officer of Laureate at (609) 919-3350 or by e-mail at Robert.Broeze@Laureatepharma.com.

142103

NMSS/RCN1 MATERIAL 8-002

Sincerely,



Safeguard Scientifics, Inc.
By: Brian J. Sisko
Its: Senior Vice President and General Counsel

Saints Capital Dakota, L.P.
By: Saints Capital Dakota, LLC
Its: General Partner

By: _____
Name: Kenneth B. Sawyer
Title: Managing Director, Saints
Capital Dakota, LLC


Laureate Pharma, Inc.
By: Robert J. Broeze, PhD
President and Chief Executive Officer

Sincerely,

Safeguard Scientifics, Inc.
By: Brian J. Sisko
Its: Senior Vice President and General Counsel

Saints Capital Dakota, L.P.
By: Saints Capital Dakota, LLC
Its: General Partner

By: _____
Name: Kenneth B. Sawyer
Title: Managing Director, Saints
Capital Dakota, LLC



Laureate Pharma, Inc.
By: Robert J. Broeze, PhD 3/6/08
President and Chief Executive Officer

Sincerely,

Safeguard Scientifics, Inc.


By: Brian J. Sisko

Its: Senior Vice President and General Counsel

Saints Capital Dakota, L.P.

By: Saints Capital Dakota, LLC

Its: General Partner

By: 

Name: Kenneth B. Sawyer

Title: Managing Director, Saints
Capital Dakota, LLC

Laureate Pharma, Inc.

By: Robert J. Broeze, PhD

President and Chief Executive Officer

Attachment 1

**INFORMATION SUPPORTING REQUEST FOR
PRIOR WRITTEN CONSENT TO INDIRECT TRANSFER OF CONTROL**

March 7, 2008

This information is submitted consistent with Consolidated Guidance About Materials Licenses – Guidance About Changes of Control and About Bankruptcy Involving Byproduct, Source, or Special Nuclear Materials Licenses, U.S. Nuclear Regulatory Commission, NUREG - 1556, Vol.15 (November 2000).

Section 5.1 **DESCRIPTION OF TRANSACTION**

1. *A complete clear description of the transaction, including any transfer of stocks or assets, mergers, etc., so that legal counsel is able, when necessary, to differentiate between name changes and changes of ownership.*

Currently, Safeguard Delaware, Inc. (“SDI”), a wholly owned subsidiary of Safeguard Scientifics, Inc. (“Safeguard”), is the sole owner of Laureate Pharma, Inc. (“Laureate”). By way of a purchase agreement by and between Saints Capital Dakota, L.P. (“Saints”) and Safeguard, Saints will purchase all of SDI’s ownership in Laureate and Saints will become the sole owner of Laureate. Laureate will be unchanged by the transaction, except that it will be wholly-owned by Saints rather than Safeguard.

Saints is a limited partnership organized under the laws of the State of Delaware. Saints is an investment fund affiliated with Saints Capital, a leading, global direct secondary investor focused on acquiring and managing venture capital and private equity investments across the technology, healthcare, consumer and industrial sectors. Headquartered in San Francisco, with investment professionals in Europe and Asia, Saints Capital currently manages ten funds with investments in over a hundred individual companies totaling over a billion dollars in originally invested capital. Saints Capital assists venture and private equity funds, corporate venture capital groups, financial institutions, crossover funds, entrepreneurs, and other investment entities achieve liquidity. Saints Capital also assists in the restructuring of venture funds in conjunction with the current general and limited partners. Saints Capital also provides merger and acquisition and private placement advisory services to consumer, technology and healthcare companies.

Safeguard Scientifics, Inc., a Pennsylvania corporation (“Safeguard”) (NYSE:SFE), is a holding company that builds value in growth-stage technology and life sciences business by providing capital, as well as a range of strategic, operational and management resources. Safeguard has 34 employees, all of whom are U.S. citizens and all work out of its headquarters in Wayne, Pennsylvania.

2. *The new name of the licensed organization. If there is no change, the licensee should so state.*

There is no planned change in the name of the Licensee in connection with this indirect transfer of control. However, if at some future time a name change is desired, the administrative change will be requested separately.

3. *The new licensee contact and telephone number(s) to facilitate communications.*

The Licensee contact and telephone information will remain the same. Contact information for Laureate is as follows:

Laureate Pharma, Inc.
201 College Road East
Princeton, New Jersey 08540
Phone: (609) 919-3300
Fax: (609) 520-3963

Section 5.2 **CHANGES OF PERSONNEL**

1. *Any changes in personnel having control over licensed activities (e.g., officers of a corporation and any changes in personnel named in the license such as radiation safety officer, authorized users, or any other persons identified in previous license applications as responsible for radiation safety or use of licensed material). The licensee should include information concerning the qualifications, training and responsibilities of new individuals.*

Following the proposed transfer, the current Laureate management team and personnel will remain the same. Laureate currently plans to continue the employment of all personnel involved in licensed activities in accordance with all requirements in the license and applicable regulations and, in the event replacement of employees becomes necessary, only individuals of comparable or otherwise appropriate qualifications and experience will be hired.

Robert J. Broeze, PhD, President and Chief Executive Officer of Laureate Pharma, Inc. will remain as a director. Michael Callaghan, Chairman of Saints Capital and a Canadian citizen, and Kenneth B. Sawyer, a U. S. citizen and the Managing Director of Saints Capital Dakota, LLC, which is the General Partner of Saints, will also become directors of Laureate.

2. *An indication of whether the transferor will remain in non-licensed business without the*

license.

Upon closing of the proposed transaction, Safeguard and SDI will no longer have any ownership in Laureate, and Saints will own 100% of Laureate.

Section 5.3 CHANGES OF LOCATION, EQUIPMENT & PROCEDURES

1. *A complete description of any planned changes in organization, location, facility, equipment, or procedures (i.e., changes in operating or emergency procedures).*

There are no planned changes in the organization, location, facility, equipment, or procedures.

2. *A detailed description of any changes in the use, possession, location or storage of the licensed materials.*

There are no planned changes in the use, possession, location or storage of the licensed materials in connection with the proposed indirect transfer of control.

3. *Any changes in organization, location, facilities, equipment, procedures, or personnel that would require a license amendment even without the change of ownership.*

There are no planned changes in the organization, facilities, equipment, procedures, or personnel that would require a license amendment even without the change of ownership.

Section 5.4 SURVEILLANCE RECORDS

1. *An indication of whether all surveillance items and records (e.g., calibrations, leak tests, surveys, inventories, and accountability requirements) will be current at the time of transfer. A description of the status of all surveillance requirements and records should also be provided.*

Applicable surveillance items and records will be current at the time of transfer and will continue to be maintained in accordance with the license and NRC regulations and will not be impacted in anyway by the proposed indirect transfer of control.

Section 5.5 DECOMMISSIONING AND RELATED RECORDS TRANSFERS

1. *Confirmation that all records concerning the safe and effective decommissioning/closure of the facility: public dose and waste disposal by release to sewers, incineration, radioactive material spills, and on-site burials, have been transferred to the new licensee if licensed activities will continue at the same location.*

All records of previous decommissioning/closure activities, including decommissioning studies of the site, reside with the licensee at the location where they are currently stored. Therefore, no records transfer is required.

2. *A description of the status of the facility. Specifically, the presence or absence of*

contamination should be documented. If contamination is present, will decontamination occur before transfer? If not, is the transferee knowledgeable of the extent and levels of contamination and applicable decommissioning requirements, and does the transferee agree to assume full liability for the decontamination of the facility or site?

There is no known site contamination as documented by the most recent site surveys.

3. *A description of any decontamination plans, including financial surety arrangements of the transferee. This should include information about how the transferee and transferor propose to divide the transferor's assets and responsibility for any cleanup needed at the time of transfer.*

There is no change in the decommissioning plans associated with this indirect transfer of control and all current assets and responsibilities of the licensee will remain with the licensee.

Section 5.6 TRANSFEREE'S COMMITMENT TO ABIDE BY THE TRANSFEROR'S COMMITMENTS

1. *Confirmation that the transferee agrees to abide by all commitments and representations previously made by the transferor. These include, but are not limited to: maintaining decommissioning records; implementing decontamination activities and decommissioning of the site; and completing corrective actions for open inspection items and enforcement actions.*

With regard to contamination of facilities and equipment, the transferee should confirm, in writing, that it accepts full liability for the site, and should provide evidence of adequate resources to fund decommissioning; or the transferor should provide a commitment to decontaminate the facility before the change of control or ownership.

With regard to open inspection items, etc., the transferee should confirm, in writing, that it accepts full responsibility for open inspection items and/or any resulting enforcement actions; or the transferee proposes alternative measures for meeting the requirements; or the transferor provides a commitment to close out all such actions with NRC before license transfer.

Following the transaction, Saints and Laureate agree to abide by all commitments and representations previously made by Laureate – including any decommissioning commitments. The proposed change in ownership will not affect these commitments and representations.

There is no known site contamination as documented by the most recent site surveys.

The NRC issued a Level IV Notice of Violation (Level I is the most severe) to the Licensee on December 8, 2005. In a letter dated January 9, 2006, the NRC acknowledged the corrective and preventative actions taken by the Licensee and stated that these actions would be examined during a future inspection. The licensed facility has not been inspected since that time. Saints has been provided copies of all applicable documentation. No further corrective actions are pending.

2. *Documentation that the transferor and transferee agree to the change in ownership or control of the licensed material and activity, and the conditions of the transfer; and the transferee is*

made aware of all open inspection items and its responsibility for possible resulting enforcement actions.

The agreement documenting the change in ownership is the Purchase Agreement by and among Saints and Safeguard, dated as of February 29, 2008. This document is part of a public filing by Safeguard with the Securities and Exchange Commission ("SEC") and is available through the SEC's Edgar service (www.sec.gov/edgar.shtml). The status of open inspection items is discussed above.

3. *A commitment by the transferee to abide by all constraints, conditions, requirements, representations, and commitments identified in the existing licenses. If not, the transferee must provide a description of its program to ensure compliance with the license and regulations.*

Following the transaction, Saints and Laureate are committed to abide by all constraints, conditions, requirements, representations, and commitments identified in the existing license. The proposed indirect transfer of control will not affect these license constraints, conditions, requirements, representations, and commitments.

This is to acknowledge the receipt of your letter/application dated

3/7/2002, and to inform you that the initial processing which includes an administrative review has been performed.

Notification 29-21189-01
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 142103.

When calling to inquire about this action, please refer to this control number. You may call us on (610) 337-5398, or 337-5260.